Related Experiment Video
Updated: Jul 20, 2026
05:15
Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
Published on: July 27, 2022
Gene therapy in cardiac arrhythmias
S V Praveen1, Johnson Francis, K Venugopal
1Department of Cardiology, Medical College, Calicut, Kerala, India. praveensv2001@yahoo.com
Indian Pacing and Electrophysiology Journal
|September 1, 2006
Summary
Gene therapy is now a reality for treating diseases, including heart rhythm disorders. Research explores gene-based pacemakers and genetic modifications for conditions like atrial fibrillation and long QT syndrome.
Area of Science:
- Cardiovascular Medicine
- Gene Therapy
- Molecular Cardiology
Background:
- Gene therapy has advanced from experimental concept to clinical application for various human diseases.
- Its scope has expanded to include cardiovascular conditions such as vascular angiogenesis and cardiac arrhythmias.
Purpose of the Study:
- To review the evolving applications of gene therapy in managing cardiovascular diseases, particularly arrhythmias.
- To highlight potential gene-based strategies for conditions like heart failure and congenital long QT syndrome.
Main Methods:
- Discussion of gene-based biological pacemakers utilizing viral vectors or mesenchymal cells in preclinical models.
- Exploration of genetic modifications targeting the AV node and ion channels.
- Identification of targets for modulating calcium cycling in failing hearts.
Main Results:
- Gene-based pacemakers show promise for stable heart rates via left bundle branch modification.
- Genetic strategies may offer therapeutic benefits for atrial fibrillation and congenital long QT syndromes.
- Modulating calcium cycling proteins is a potential avenue for treating arrhythmias in heart failure.
Conclusions:
- Gene therapy presents promising avenues for treating complex cardiac arrhythmias and related conditions.
- Further research and ethical considerations are essential for clinical translation of these gene-based approaches.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:28Mechanism of Cardiac Arrhythmias
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
01:29Disturbances in Heart Rhythm
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...